Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: A comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil

European Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2015, Pages 95-106

  Ling, Jing ^a   Shi, Jun ^b   Jiang, Qiudi ^b   Jiao, Zheng ^a  

^a FUDAN UNIVERSITY   (China)

^b Roche Innovation Center Shanghai   (China)

Author keywords

Enterohepatic circulation; Ethnic differences; Mycophenolic acid; Population pharmacokinetics

Indexed keywords

7 O MYCOPHENOLIC ACID GLUCURONIDE; DRUG METABOLITE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; UNCLASSIFIED DRUG; GLUCURONIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID GLUCURONIDE;

ARTICLE; CAUCASIAN; CHINESE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; ENTEROHEPATIC CIRCULATION; ETHNIC DIFFERENCE; FEMALE; GALLBLADDER EMPTYING; HUMAN; HUMAN EXPERIMENT; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; ADULT; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; MIDDLE AGED; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; YOUNG ADULT;

EID: 84922093075     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1771-1     Document Type: Article

References (45)

1. USRDS (2013) Annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States, (2013) National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. http://www.usrds.org/2013/pdf/v2-ch7-13.pdf. Accessed 7 Oct 2014
2. Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2-3):85-118
3. Bullingham RE, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34(6):429-455
4. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33(1):139-146. doi:10.1124/dmd.104.001651
5. Staatz CE, Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46(1):13-58. doi:10.2165/00003088-200746010-00002
6. Cho EK, Han DJ, Kim SC, Burckart GJ, Venkataramanan R, Oh JM (2004) Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol 44(7):743-750. doi:10.1177/0091270004266634
7. Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K (2004) The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc 36(7):2076-2078. doi:10.1016/j.transproceed.2004.08.087
8. Tsang WK, Tong KL, Yeung S, Lee W, Chan HW (2000) Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. Transplant Proc 32(7):1755-1756
9. Wang X, Tang X, Xu D (1998) Immunosupressive effect of mycophenolate mofetil with two different dosages in cadaveric renal transplantation:a short study. Transplant Proc 30(7):3573-3574
10. Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y, Zhong MK, Lu WY (2008) Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol 65(6):893-907. doi:10.1111/j.1365-2125.2008.03109.x
11. Jiang C, Chen H, Gui L, Pei Q (2009) Relative bioavailability and bioequivalence of mycophenolate mofetil in healthy volunteers. J Hunan Environ-Biol Polytech 15(4):13-17
12. Bullingham R, Monroe S, Nicholls A, Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36(4):315-324
13. Naderer OJ, Dupuis RE, Heinzen EL, Wiwattanawongsa K, Johnson MW, Smith PC (2005) The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol 45(2):219-226. doi:10.1177/0091270004271555
14. Geng F, Jiao Z, Dao YJ, Qiu XY, Ding JJ, Shi XJ, Li ZD, Zhong MK (2012) The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin Chim Acta Int J Clin Chem 413(7-8):683-690. doi:10.1016/j.cca.2011.12.003
15. Jiao Z, Zhong JY, Zhang M, Shi XJ, Yu YQ, Lu WY (2007) Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 63(1):27-37. doi:10.1007/s00228-006-0215-y
16. Liang MZ, Lu YP, Nan F, Li YP (2006) Pharmacokinetics of mycophenolic acid and its glucuronide after a single and multiple oral dose of mycophenolate mofetil in Chinese renal transplantation recipients. Transplant Proc 38(7):2044-2047. doi:10.1016/j.transproceed.2006.06.027
17. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman K (2000) Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 40(6):624-633
18. Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, Falk MC, Nicol D (1999) The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 66(5):492-500. doi:10.1016/s0009-9236(99)70012-3
19. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schutz E, Mehls O, Oellerich M, Armstrong VW, Tonshoff B (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. J Am Soc Nephrol 9(8):1511-1520
20. Shen B, Li S, Zhang Y, Yuan X, Fan Y, Liu Z, Hu Q, Yu C (2009) Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed Anal 50(3):515-521. doi:10.1016/j.jpba.2009.05.030
21. Xia DY, Gao FR, Qin HX, Yan M (2008) Pharmacokinetics of mycophenolate mofetil in Chinese healthy volunteers. Pharm J Chin PLA 24(3):218-220
22. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G, Voihsel M, Braun F, Oellerich M (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126(5):1075-1082. doi:10.1038/sj.bjp.0702399
23. BIC selection procedures in mixed effects models (2012) INRIA. http://hal.inria.fr/docs/00/69/64/35/PDF/RR-7948.pdf. Accessed 7 Oct 2014
24. Vaida F, Blanchard S (2005) Conditional Akaike information for mixed-effects models. Biometrika 92(2):351-370. doi:10.1093/biomet/92.2.351
25. Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, Dong J, Ruiz-Garcia A, Sweeney K, Cronenberger C (2013) Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2:e51. doi:10.1038/psp.2013.26
26. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41(10):751-790. doi:10.2165/00003088-200241100-00005
27. Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA (2011) The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet 50(1):1-24. doi:10.2165/11536640-000000000-00000
28. Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34(5):711-726. doi:10.1007/s10928-007-9066-0
29. Laporte-Simitsidis S, Girard P, Mismetti P, Chabaud S, Decousus H, Boissel JP (2000) Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it? J Pharm Sci 89(2):155-167. doi:10.1002/(SICI)1520-6017(200002)89:2〈155::AID-JPS3〉3.0.CO;2-2
30. Wakefield J, Rahman N (2000) The combination of population pharmacokinetic studies. Biometrics 56(1):263-270
31. Boeckmann AJ, Sheiner LB, Beal SL (2013) NONMEM user's guides. Icon Development Solutions Ellicott City, MD
32. Pitsiu M, Hussein Z, Majid O, Aarons L, de Longueville M, Stockis A (2004) Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. Br J Clin Pharmacol 57(4):402-411. doi:10.1046/j.1365-2125.2003.02017.x
33. Anderson BJ, Holford NH (2008)Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303-332. doi:10.1146/annurev.pharmtox.48.113006.094708
34. Efron B, Gong G (1983) A leisurely look at the bootstrap, the jackknife and cross-validation. Am Stat 37(1):36-48
35. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503-512
36. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28(2):171-192
37. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA (2012) Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol 73(5):727-740. doi:10.1111/j.1365-2125.2011.04140.x
38. Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, van Kan E, Paul L, de Fijter J (2005) Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 60(3):249-256. doi:10.1111/j.1365-2125.2005.02398.x
39. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C (2004) Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14(8):501-515
40. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78(4):351-361. doi:10.1016/j.clpt.2005.06.007
41. Levesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C (2007) The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 81(3):392-400. doi:10.1038/sj.clpt.6100073
42. Sanchez-Fructuoso AI, Maestro ML, Calvo N, Viudarreta M, Perez-Flores I, Veganzone S, De la Orden V, Ortega D, Arroyo M, Barrientos A (2009) The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant Proc 41(6):2313-2316. doi:10.1016/j.transproceed.2009.06.038
43. van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T (2009) UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 86(3):319-327. doi:10.1038/clpt.2009.83
44. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ (2005) Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 15(5):295-301
45. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Shirao K, Tamura T, Yamamoto N, Kunitoh H, Hamaguchi T, Yoshida T, Kubota K, Ohtsu A, Muto M, Minami H, Saijo N, Kamatani N, Sawada JI (2006) Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 6(1):63-75. doi:10.1038/sj.tpj.6500335